{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:05:36Z","timestamp":1761717936246},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.clindermatol.2004.01.008","type":"journal-article","created":{"date-parts":[[2004,10,7]],"date-time":"2004-10-07T15:04:01Z","timestamp":1097161441000},"page":"319-324","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacotherapy of obesity"],"prefix":"10.1016","volume":"22","author":[{"given":"Yvonne","family":"Linn\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"R\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2004.01.008_BIB1","series-title":"Contemporary diagnosis and management of obesity","author":"Bray","year":"1998"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016","article-title":"Use and abuse of appetite-suppressant drugs in the treatment of obesity","volume":"119","author":"Bray","year":"1993","journal-title":"Ann Int Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Conolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30698-8","article-title":"Behavioral management of obesity","volume":"73","author":"Brownell","year":"1989","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB5","series-title":"Weighing the options. Critera for evaluating weight management programs","author":"Thomas","year":"1995"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity","volume":"1","author":"R\u00f6ssner","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1464-5491.1995.tb00504.x","article-title":"The comparison of four weight reducing strategies aimed at overweight diabetic patients","volume":"12","author":"Jung","year":"1995","journal-title":"Diabetes Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/jc.77.5.1287","article-title":"Relative effects of calorie restriction and weight loss in non-insulin-dependent diabetes mellitus","volume":"77","author":"Kelley","year":"1993","journal-title":"J Clin Endo Metab"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archinte.150.4.803","article-title":"Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes melltius","volume":"150","author":"Watts","year":"1990","journal-title":"Arch Int Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a009158","article-title":"Body fat distribution and risk on non-insulin-dependent diabetes mellitus in women","volume":"145","author":"Carey","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2004.01.008_BIB13","article-title":"Sibutramine","volume":"21","author":"Lean","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB15","unstructured":"Smith IG on behalf of the members of the Sibutramine Clinical Study 1047 team, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505\u201312"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type II diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"issue":"suppl 3","key":"10.1016\/j.clindermatol.2004.01.008_BIB18","article-title":"The UK Prospective Diabetes Study. A review","volume":"21","author":"Turner","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2337\/diacare.21.9.1489","article-title":"Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin","volume":"21","author":"Damsbo","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-73-6-1294","article-title":"Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects","volume":"73","author":"DeFronzo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB23","first-page":"394","article-title":"One year comparative trial of metformin and glipizide in type 2 diabetes mellitus","volume":"20","author":"Campbell","year":"1994","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB24","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1542\/peds.107.4.e55","article-title":"The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes","volume":"107","author":"Freemark","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1054-139X(01)00202-6","article-title":"Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS)","volume":"29","author":"Glueck","year":"2001","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","article-title":"Metformin for weight loss in pediatric patients taking psychotropic drugs","volume":"159","author":"Morrison","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB28","first-page":"269","article-title":"The effect and safety of an ephedrine caffeine compound compared to ephedrine, caffeine and placebo in obese","volume":"16","author":"Astrup","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.289.12.1537","article-title":"Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance","volume":"289","author":"Shekelle","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting","volume":"69","author":"Hill","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients","volume":"248","author":"Lindg\u00e4rde","year":"2000","journal-title":"J Int Med"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/sj.ijo.0801391","article-title":"Short communication. Referral letters to an obesity unit \u2013 relationship between doctor and patient information","volume":"24","author":"Linn\u00e9","year":"2000","journal-title":"Int J Obes"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/oby.2001.88","article-title":"Long-term medication use and weight loss maintenance","volume":"9","author":"Womble","year":"2001","journal-title":"Obes Res"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB35","series-title":"Orlistat for the treatment of obesity. Development and Evaluation Committee Report 101","author":"Foxcroft","year":"1999"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20014091091661","article-title":"Alternative treatment for weight loss. A critical review","volume":"41","author":"Allison","year":"2001","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14656566.3.5.599","article-title":"Orlistat in the treatment of type 2 diabetes mellitus","volume":"3","author":"Kelley","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB38","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2165\/00003495-200161140-00011","article-title":"Orlistat in the prevention and treatment of type 2 diabetes mellitus","volume":"61","author":"Keating","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.clindermatol.2004.01.008_BIB39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","article-title":"The effects of orlistat on weight and on serum lipids in obese patients with hypercholestolemia","volume":"25","author":"Muls","year":"2002","journal-title":"Int J Obes Relat Metab Disord"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X04000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X04000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T06:00:21Z","timestamp":1549173621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X04000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0738081X04000094"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2004.01.008","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}